VST for BK Virus in Kidney Transplant Recipients

Phase 1, open-label, single-arm trial in BK virus infection, sponsored by University of Wisconsin–Madison. Primary endpoints: Incidence of Adverse Events up to 4 hours post Cell Infusion, Incidence of Adverse Events up to 4 weeks of T-cell Transfer and 3 more. Started Dec 2021; status: completed.